Investigating blood markers in juvenile idiopathic arthritis
Angiogenic Inflammatory Biomarkers in Juvenile Idiopathic Arthritis
Assistance Publique - Hôpitaux de Paris · NCT05534347
This study is testing if certain blood markers can help predict how severe juvenile idiopathic arthritis will be in young patients as they move from pediatric to adult care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 16 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris (other) |
| Locations | 1 site (Paris, IDF) |
| Trial ID | NCT05534347 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate whether serum inflammatory angiogenic markers, such as semaphorins and CCN1, can predict the severity of juvenile idiopathic arthritis (JIA) by assessing structural progression and therapeutic escalation. The research focuses on patients transitioning from pediatric to adult care, examining the relationship between these biomarkers and disease severity. By analyzing blood samples and joint punctures, the study seeks to establish predictive parameters for JIA severity, similar to findings in rheumatoid arthritis.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 16 and older diagnosed with juvenile idiopathic arthritis who are receiving specialized follow-up in rheumatology.
Not a fit: Patients under curatorship or guardianship, or those receiving French state medical aid, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new method for predicting disease severity in juvenile idiopathic arthritis, leading to better management and treatment strategies.
How similar studies have performed: Previous studies have shown success in using angiogenic biomarkers to predict severity in rheumatoid arthritis, suggesting potential applicability in juvenile idiopathic arthritis.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Greater than or equal to 16 years-old * Diagnosis of Juvenile Idiopathic Arthritis with specialized follow up in Rheumatology at Cochin Hospital * No-opposition to the research * Patient with health insurance * Mastery of the French language Exclusion Criteria: * Patient under curatorship or guardianship * Patient receiving french state medical aid
Where this trial is running
Paris, IDF
- Rheumatology Department, Cochin Hospital — Paris, IDF, France (RECRUITING)
Study contacts
- Principal investigator: Yannick ALLANORE, PD, PhD — Cochin Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP)
- Study coordinator: Yannick ALLANORE, PD, PhD
- Email: yannick.allanore@aphp.fr
- Phone: 0033158412563
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Juvenile Idiopathic Arthritis, Juvenile idiopathic arthritis, JIA patients in transition towards adult ward, Prognosis of JIA, Severity and structural damage in JIA, Angiogenic and inflammatory biomarkers, Semaphorin, CCN1, Serum fluid